Antibody responses to<i>Plasmodium falciparum</i>sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas.

Ferreira-da-Cruz, M. F.; Deslandes, D.; Oliveira-Ferreira, Joseli; Montenegro-James, S.; Tartar, André; Druilhe, Pierre; Daniel-Ribeiro, C. T.

doi:10.1051/parasite/1995021023

Cited by 13 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies of residents of South America, Papua New Guinea, India, and Africa have demonstrated varying frequencies of antibodies to LSA-1 synthetic peptides and recombinant proteins. 12,14,18,20,21,24 Unlike the current report, antibodies in these studies were evaluated at only one time point. The frequency of antibodies to LSA-Rep, a sequence that includes the EQ repeat evaluated in the current report, ranged from 17% in a non-immune population that migrated to a malaria- 14,24 Our finding that 32.1% of the individuals had IgG antibodies to a central repeat region peptide is in the mid-range of these prior studies.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission.

John¹,

Ouma²,

Sumba³

et al. 2002

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Lymphocyte proliferation and antibody responses to five peptides corresponding to the N-and C-terminal non-repeat and central repeat regions of Plasmodium falciparum liver-stage antigen-1 (LSA-1) were examined in residents of a highland area of Kenya where malaria transmission is episodic and varies with rainfall. The frequency of lymphocyte proliferation responses (stimulation index > 2) by children (persons Յ 6 years old) and adults (persons Ն 18 years old) was similar and did not differ significantly across seasons. In contrast, the proportion of individuals with IgG antibodies to LSA-1 peptides was higher in the rainy than dry season, and the frequency of these responses was greater for adults than children (39.4% versus 18.7% during the period of high transmission; P ‫ס‬ 0.009). Antibodies to LSA-1 were primarily of the IgG1 and IgG3 subclasses, and these also varied with season (30.1% and 32.5% of individuals had IgG1 and IgG3 in the rainy season versus none and 10.9% in the dry season). There was no significant difference in the time to re-infection between groups of persons with or without IgG antibody or lymphocyte proliferation responses to LSA-1 peptides. These data indicate that age and transmission intensity independently affect IgG antibody responses to LSA-1 but do not influence lymphocyte proliferation in this highland area where malaria transmission is highly variable.

show abstract

Section: Discussionmentioning

confidence: 94%

“…An agerelated increase in the prevalence or level of LSA-1 antibodies was reported in five of the seven areas in which both children and adults were evaluated. 14,24 This increase was seen in areas of both high and low transmission.…”

Section: Discussionmentioning

confidence: 94%

Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission.

John¹,

Ouma²,

Sumba³

et al. 2002

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…Such results agreed with those previously reported in other endemic areas. 18 Conversely, in Burkina Faso, the anti-NANP antibody level was directly related to the rate of sporozoite inoculation but not to protection against infection. 6 As observed with anti-NANP antibody, anti-NAAG antibody was not related to P. falciparum infection rate or reinfection delay, or to infection with P. malariae at enrollment or during the follow-up.…”

Section: Discussionmentioning

confidence: 96%

Factors influencing resistance to reinfection with Plasmodium falciparum.

Domarle

Migot-Nabias²,

Mvoukani³

et al. 1999

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. A treatment-reinfection study design was used to investigate the relationships between host immunologic and/or genetic factors and resistance to reinfection with Plasmodium falciparum. Sixty-one children in Gabon were enrolled in a cross-sectional study to measure the prevalence of each human plasmodial species. All were given amodiaquine for radical cure of parasites, and 40 were subsequently followed-up for 30 weeks. Successive blood smears were examined to measure the delay of reappearance in blood of asexual stages of P. falciparum parasites. Presence of infection during the cross-sectional survey was associated with male sex, non-deficient glucose-6-phosphate dehydrogenase activity, plasma interleukin-10 level, and anti-LSA-Rep antibody concentration. Resistance to reinfection was related to the presence of anti-LSA-J antibodies, and the absence of anti-LSA-Rep antibodies. Moreover, P. malariae-infected subjects were usually co-infected with P. falciparum, and were also more rapidly reinfected with P. falciparum after treatment, compared with those without P. malariae infection.Most studies aimed to investigate the protection against Plasmodium falciparum malaria have used malaria attacks as criteria.1,2 However, these criteria require long and precise follow-up of the populations because malaria attacks occur rarely, even in hyperendemic areas where children who present more than 2 malaria attacks per year are rare. 3 Moreover, such criteria mainly investigate protection against blood stages of the parasite and do not allow the assessment of protection against the pre-erythrocytic stages. The existence of such protection is shown by the fact that only a small proportion part of infective bites leads to the appearance of parasites in the peripheral blood. 4 Similarly, the prevalence rates of blood parasite infections following antimalarial treatment are extremely lower than presumed in view of the number of infective bites from mosquitoes. 5 In this context, effector mechanisms may be directed against the sporozoites, the liver stages, or both. Protection against the sporozoites may result from a specific humoral response because it has been demonstrated for the antibody directed to the repetitive epitope (NANP) 3 from the circumsporozoite (CS) protein. 6 Antibody targeted against liver-stage antigens may also contribute to the reduction of the emergence of P. falciparum from the liver. The plasma levels of Th1-type and Th2-type cytokines are also thought to play a major role in individual levels of protection. To evaluate the level of protection against the sporozoite and liver stages of the parasite, we first performed a cross-sectional study to assess the parasitologic status of children living in Gabon, an area hyperendemic for malaria. All children then received a curative antimalarial treatment and were enrolled in a longitudinal follow-up to measure their delay of reinfection by natural challenge. Relationships between the immunologic factors and the infection rate at the beginning of the s...

show abstract

“…The protection induced in human volunteers immunized with irradiated P. falciparum sporozoites has been correlated with a proliferative T-cell response from three LSA-1 epitopes (T1, T3, and T5) (73). This protein has been considered to be a candidate for a vaccine against P. falciparum due to the high prevalence of antibodies against LSA-1 among the African population (37,66).…”

Section: Liver-stage Antigen 1 (Lsa-1)mentioning

confidence: 99%

Developmental Biology of Sporozoite-Host Interactions inPlasmodium falciparumMalaria: Implications for Vaccine Design

2006

View full text Add to dashboard Cite

SUMMARY The Plasmodium falciparum sporozoite infects different types of cells in a mosquito's salivary glands and human epithelial and Kuppfer cells and hepatocytes. These become differentiated later on, transforming themselves into the invasive red blood cell form, the merozoite. The ability of sporozoites to interact with different types of cells requires a wide variety of mechanisms allowing them to survive in both hosts: mobility, receptor-ligand interactions with different cellular receptors, and transformation and development into other invasive parasite forms, which are vitally important for parasite survival. Sporozoite complexity is reflected in the large quantity of proteins that can be expressed. Some of them have been extensively studied, such as CSP, TRAP, STARP, LSA-1, LSA-3, SALSA, SPECT1, SPECT2, MAEBL, and SPATR, due to their importance in infection and their potential use as vaccines. Our work has been focused on the search for the molecular mechanisms of parasite-host cellular receptor-ligand interactions by identifying amino acid sequences and the critical binding residues from these proteins relevant to parasite invasion. Once such sequences have been identified, it will be possible to modify them to induce a strong immune response against P. falciparum in the experimental Aotus monkey model. This all leads towards developing multistage, multicomponent, subunit-based vaccines that will be effective in eradicating or controlling malaria caused by P. falciparum.

show abstract

Antibody responses toPlasmodium falciparumsporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas.

Cited by 13 publications

References 1 publication

Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission.

Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission.

Factors influencing resistance to reinfection with Plasmodium falciparum.

Developmental Biology of Sporozoite-Host Interactions inPlasmodium falciparumMalaria: Implications for Vaccine Design

Contact Info

Product

Resources

About